智通财经APP获悉，远程医疗公司Hims & Hers ...

但当 HIMS 在 12 月 6 日达到其最后一个波动高点时（使用收盘价），该股的收盘价为 34.23 美元，仅比其 50 天移动平均线 23.29 美元高出 47%。同样，其 2024 年 6 月 18 日的波动高点比当时的 50 天移动平均线高出 ...

Hims & Hers Health reported fourth-quarter results on Monday that beat analysts' expectations, but the stock sank in extended ...

Shares of Hims & Hers Health plunged Friday after the Food & Drug Administration said a shortage of the active ingredient in ...

After the FDA removed semaglutide injection products from a shortage list, compounders like Hims have 60-90 days to stop ...

Hims & Hers Health (HIMS) has seen its shares decline over 17% in the past week since the U.S. Food and Drug Administration (FDA) announced ...

Hims & Hers Health生产司美格鲁肽的配方药，但美国法规规定，只有在该成分处于短缺状态时，该公司才能合法生产。因此，随着FDA宣布短缺结束，Hims & Hers在该领域的业务可能会受到一定影响。

Shares of Hims & Hers Health ( HIMS -25.79%) are falling on Friday. The company's stock lost 23.2% as of 1 p.m. ET and lost ...

The ruling shows Novo Nordisk’s confidence that the supply of semaglutide will be stable for now.

Shares of Hims & Hers Health (HIMS) shares plunged in late trading Monday after the company reported falling margins as costs ...

Hims & Hers的股价近期大幅下跌。上周五，在美国食品药品监督管理局（FDA）宣布司美格鲁肽注射产品的短缺问题已解决后，公司股价暴跌26%。去年五月，Hims & ...